This invention pertains to compounds having the structure: ##STR00001## wherein m is 0, 1, 2, or 3; R.sub.2 is a substituted or unsubstituted imidazole or pyrazole wherein the point of attachment of R.sub.2 to the alkyl chain is not N; R.sub.5 is a hydrogen atom or a substituted or unsubstituted alkyl, aryl, or alkylaryl moiety; and R.sub.7 is a halogen atom, C.sub.1-C.sub.4 alkyl, OH, O-alkyl(C.sub.1-C.sub.4), NH.sub.2, or NH-alkyl(C.sub.1-C.sub.4), which specifically inhibit the adenosine A1 and A3 receptors and the use of these compounds to treat a disease associated with A3 adenosine receptor in a subject, comprising administering to the subject a therapeutically effective amount of the compound.